用于体外循环管材的新型醛基化海藻酸钠-地塞米松缓释涂层研究

doi:10.3969/j.issn.0258-8021.2014. 06.014

摘要
图/表
参考文献
相关文章 (4)

全文: PDF (2275 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要研制新型醛基化海藻酸钠-地塞米松缓释涂层，筛选最佳涂层模式和涂层条件，对涂层稳定性、抗凝性能、缓释性能等进行评价。高碘酸钠氧化海藻酸钠得醛基化海藻酸钠（OSA），酸化预处理聚氯乙烯（PVC）管材表面，聚乙烯亚胺涂抹经酸化预处理的PVC管材。聚乙烯亚胺涂层管材（PP）通过离子键直接交联地塞米松磷酸钠（DSP）制备DSP单涂层管材（PPD组），PP通过离子键交联（PPI组）、共价键交联（PPC组）两种方式制备醛基化海藻酸钠-地塞米松磷酸钠复合涂层管材，同时设置空白对照（C组）。以正交实验筛选3种涂层模式的最佳涂层条件。对3种涂层管材进行涂层物定性和定量分析，抗凝、抗血小板、抗蛋白粘附、体外释放等性能进行评价研究，从而筛选最佳涂层模式。结果显示，PPD、PPI和PPC等3种涂层模式均能固定DSP，最佳固定密度分别为(333±075)、(163±076)
、(206±068)μg/cm2；复合涂层组（PPI和PPC）血小板粘附量（109/L）分别为（1388±189）和（1913±340），均较C组（4138±320）显著减少；复合涂层组蛋白粘附量（mg/cm2）（HAS：（2986±1357）和（4667±320），HPF：（3499±352）和（4567±379）），均较PPD组（HAS：（6873±426），HPF：（7254±790））显著减少；体外释放方面PPC组明显优于PPI组。醛基化海藻酸钠-地塞米松复合涂层具备良好的血液相容性和生物相容性，通过共价交联的DSP能够达到缓释效果。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	高文卿¹李彤^1*于美丽²胡晓旻¹段大为¹

关键词 ：地塞米松磷酸钠, 海藻酸钠, 缓释, 生物相容性, 血液相容性

Abstract：The aim of this work is to prepare a novel composite coating of sodium alginate and dexamethasone. By optimizing the coating mode and conditions, the properties of stability, anticoagulation and controlled release were evaluated. Polyethyleneimine (PEI) was coated on PVC pipelines surface pretreated with acidification, dexamethasone sodium phosphate (DSP) was coated on PEIcoated pipelines (PP) with ionic bond, DSP coated pipelines were created (Group PPD). Pipelines coated OSADXM composite were created by ionic bond (Group PPI) or covalent bond (Group PPC). The control group (Group C) was set as well. The optimum coating condition was obtained by the orthogonal test. By evaluating the properties of different coated pipelines including anticoagulation, platelet adhesion, protein adhesion and release in vitro, the optimum coating mode was determined. DSP can be bound to PVC surface in Group PPD, PPI and PPC. The optimum immobilization quantity of DSP on different groups are (333±075)，(163±076)，(206±068) μg/cm2. The platelet adhesion (109/L) of Group PPI and PPC (1388±189 and 1913±340) was significantly reduced than that of Group C (4138±320). The protein adhesion (mg/cm2) of Group PPI and PPC (HAS: 2986±1357 and 4667±320, HPF: 3499±352 and 4567±379) was significantly decreased than that of Group PPD (Has: 6873±426, HPF: 7254±790). The release property of Group PPC is superior to that of Group PPI. The coating of OSADXM composite exhibited improved hemocompatibility. Covalently bound DSP can be controlled released.


Key words： dexamethasone sodium phosphate sodium alginate controlled release biocompatibility hemocompatibility

基金资助:天津市科技支撑计划重点项目（11ZCGYSY02000）；天津市卫生局重点攻关项目(13KG110)

引用本文:

高文卿¹李彤^1*于美丽²胡晓旻¹段大为¹. 用于体外循环管材的新型醛基化海藻酸钠-地塞米松缓释涂层研究[J]. 中国生物医学工程学报, 2014, 33(6): 737-745.
GAO Wen Qing¹ LI Tong^1* YU Mei Li² HU Xiao Min¹DUAN Da Wei¹. Research on a Novel Sodium AlginateDexamethasone Composite Coating with MultiAldehyde Groups Applied to Extracoporeal Circuits#br#. journal1, 2014, 33(6): 737-745.

链接本文:

http://cjbme.csbme.org/CN/10.3969/j.issn.0258-8021.2014. 06.014 或 http://cjbme.csbme.org/CN/Y2014/V33/I6/737

［1］Apostolakis EE, Koletsis EN, Baikoussis NG, et al. Strategies to prevent intraoperative lung injury during cardiopulmonary bypass ［J］. J Cardiothorac Sury, 2010,11(5):1-9.［2］Suzuki Y, Daitoku K, Minakawa M, et al. Poly2methoxyethylacrylatecoated bypass circuits reduce activation of coagulation system and inflammatory response in congenital cardiac surgery ［J］. J Artif Organs, 2008, 11(3): 111-116.
［3］Finne-Wistrand A, Albertsson AC, Kwon OH, et al. Resorbable scaffolds from three different techniques: electrospun fabrics, saltleaching porous films, and smooth flat surfaces［J］. Macromol Biosci, 2008, 8(10): 951-959.
［4］Day JR, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass ［ J ］. Int J Surg, 2005, 3(2): 129-140.
［5］Sperling C, Houska M, Brynda E, et al. In vitro hemocompatibility of albuminheparin multilayer coatings on polyethersulfone prepared by the layerbylayer technique ［J］. J Biomed Mater Resa, 2006,76(4):681-689.
［6］Weber N, Wendel HP, Ziemer G. Hemocompatibility of heparincoated surfaces and the role of selective plasma protein adsorption［J］. Biomaterials, 2002, 23(2): 429-439.
［7］柏淑颖,朱德明,王伟. 涂层技术在体外循环装置中的应用及意义［J］. 中国体外循环杂志,2009,7(2):124-128.
［8］Larm O, Larsson R, Olsson P. A new nonthrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue［J］. Biomater Med Devices Artif Organs, 1983,11(2-3):161-234.
［9］Andersson LO, Hoffman J,et al. Mechanisms of anticoagulant effects of some sulphated polysaccharides［J］. Thromb Res,1982, 28(6):741-748.
［10］Nishino T, Yokoyama G, Dobashi K, et al. Isolation, purification, and characterization of fucosecontaining sulfated polysaccharides from the brown seaweed Ecklonia kurome and their bloodanticoagulant activities ［J］. Carbohydr Res, 1989,
186(1):119-148.
［11］Manju S, Muraleedharan CV. Evaluation of alginate dialdehyde crosslinked gelatin hydrogel as a biodegradable sealant for polyester vascular graft［J］. J Biomed Mater Res B Appl Biomater, 2011, 98(1):139-188.
［12］Bouhadir KH, Lee KY, Alsberg E, et al. Degradation of partially oxidized alginate and its potential application for tissue engineering ［J］. Biotechnol Prog,2001,17(5):945-995.
［13］Bron JL, Vonk LA, Smit TH, et al. Engineering alginate for intervertebral disc repair ［J］. Mech Behav Biomed Mater. 2011,4(7):1196-1205. 
［14］Popa EG, Gomes ME, Reis RL. Cell delivery systems using alginate—carrageenan hydrogel beads and fibers for regenerative medicine applications［J］. Biomacromolecules, 2011, 12(11):3952-3961. 
［15］Barnett BP, Arepally A, Stuber M, et al. Synthesis of magnetic resonance-, Xray- and ultrasound visible alginate microcapsules for immunoisolation and noninvasive imaging of cellular therapeutics ［J］. Nat Protoc, 2011, 6(8): 1142-1151.
［16］张苑，袁惠燕，吴威，等. 不透X射线栓塞微球的制备及其性质评价［J］.北京大学学报（医学版），2009, 41（4）：447-451.
［17］Park SJ, Shin S, Koo OJ, et al. Functional improvement of porcine neonatal pancreatic cell clusters via conformal encapsulation using an airdriven encapsulator ［J］. Exp Mol Med, 2012, 44(1): 20-25.
［18］Shao Shiying, Gao Yun, Xie Bing, et al. Correction of hyperglycemia in type 1 diabetic models by transplantation of encapsulated insulinproducing cells derived from mouse embryo progenitor ［J］. J Endocrinol, 2011, 208(3): 245-255.
［19］高长路，武林枫，刘颖欣，等. 微囊化兔甲状旁腺组织异种移植治疗甲状腺功能低下症的实验研究［J］. 中国普外基础与临床杂志，2006,13（3）：256-259.
［20］Weir MD, Xu HH. Human bone marrow stem cellencapsulating calcium phosphate scaffolds for bone repair［J］. Acta Biomater, 2010, 6(10): 4118-4126.
［21］Forster RE, Thürmer F, Wallrapp C. Characterisation of physicomechanical properties and degradation potential of calcium alginate beads for use in embolization ［J］. J Mater Sci Mater Med, 2010, 21(7): 2243-2251.
［22］李金友，李彤，高文卿，等. 新型醛基化海藻酸钠抗凝血涂层物制备及性能评价［J］. 中国生物医学工程学报，2012,31（6）：918-924.
［23］Checchia PA, Bronicki RA, Costello JM, et al. Steroid use before pediatric cardiac operations using cardiopulmonary bypass:an international survey of 36 centers ［ J ］. Pediatr Crit CareMed, 2005, 6(4): 441-444.
［24］Kirklin JK. The postperfusion syndrome: inflammation and the damaging effects of cardiopulmonary bypass［A］. In: Tinker JH(ed): cardiopulmonary bypass: current concept and controversies［M］. Philadelphia: W. B. Saunders, 1989: 131-146.
［25］Kirklin JK. Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass ［J］. Ann Thorac Surg, 1991, 51 (4): 529-531.
［26］Rep logle RL, Gazzaniga AB, Gross RE. Use of corticosteroids during cardiopulmonary bypass: possible lysosome stabilization［J］. Circulation, 1966, 33 (4 Suppl): 86-92.［27］王琴梅,张亦霞,李卓萍,等. 多醛基海藻酸钠交联剂的制备及性能［J］. 应用化学, 2010,27(2):155-158.
［28］Yii M, Gourlay T, Fleming J, et al. Evaluation of Carmeda bioactive surface (CBAS), Duraflo and a novel nonspecial proteasemodified surface using a new in vitro model simulating cardiopulmonary bypass［J］.Perfusion, 1996, 11(3): 229-240.
［29］Dubois M，Gilles KA，Hamilton JK，et al. Colorimetric method for determination of sugars and related substances ［J］.Analytical Chemistry, 1956, 28(3): 350-356.
［30］Ishihara K, Fukumoto K, Iwasaki Y, et al. Modification of polysulfone with phospholipid polymer for improvement of the blood compatibility. Part 1. Surface characterization ［J］.Biomaterials, 1999, 20(17):1545-1551.